Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Free Cash Flow (2020 - 2025)

Historic Free Cash Flow for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to -$28.6 million.

  • Lyell Immunopharma's Free Cash Flow rose 1840.97% to -$28.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$165.5 million, marking a year-over-year decrease of 595.46%. This contributed to the annual value of -$162.9 million for FY2024, which is 211.68% up from last year.
  • Latest data reveals that Lyell Immunopharma reported Free Cash Flow of -$28.6 million as of Q3 2025, which was up 1840.97% from -$34.6 million recorded in Q2 2025.
  • Lyell Immunopharma's 5-year Free Cash Flow high stood at -$28.6 million for Q3 2025, and its period low was -$58.4 million during Q2 2021.
  • Moreover, its 5-year median value for Free Cash Flow was -$42.2 million (2024), whereas its average is -$43.8 million.
  • In the last 5 years, Lyell Immunopharma's Free Cash Flow surged by 2215.21% in 2023 and then tumbled by 3018.28% in 2025.
  • Over the past 5 years, Lyell Immunopharma's Free Cash Flow (Quarter) stood at -$43.5 million in 2021, then fell by 3.15% to -$44.8 million in 2022, then increased by 9.34% to -$40.7 million in 2023, then decreased by 16.3% to -$47.3 million in 2024, then soared by 39.43% to -$28.6 million in 2025.
  • Its Free Cash Flow was -$28.6 million in Q3 2025, compared to -$34.6 million in Q2 2025 and -$55.0 million in Q1 2025.